InterMune Likely First To Market In IPF, But Other Firms Poised To Follow
Executive Summary
With an FDA advisory committee recommendation for approval and a May 4 PDUFA date, InterMune holds a significant lead over the rest of the field and should be first to market with a drug to treat idiopathic pulmonary fibrosis
You may also be interested in...
After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market
In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.
Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis
The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.
Doubling Its Bet In IPF, Gilead Buys Arresto Biosciences For $225 Million
Deal also calls for sales-based milestones, likely pegged to antibody currently in Phase I in idiopathic pulmonary fibrosis and advanced solid tumors.